|83.76||+0.3800||+0.46%||Vol 298.90K||1Y Perf 118.09%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||65.50||Analyst Rating||Moderate Buy 2.25|
|Potential %||-21.80||Finscreener Ranking||★+ 45.10|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 40.15|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★ 53.25|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||+ 26.10|
|Market Cap||3.54B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||91.51||Earnings Date||3rd Jun 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd Jun 2021|
|Estimated EPS Next Report||0.57|
|EPS Growth Next 5 Years %||19.00|
|Avg. Weekly Volume||414.99K|
|Avg. Monthly Volume||489.87K|
|Avg. Quarterly Volume||587.24K|
Cantel Medical Corp. (NYSE: CMD) stock closed at 83.76 per share at the end of the most recent trading day (a 0.46% change compared to the prior day closing price) with a volume of 337.33K shares and market capitalization of 3.54B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 3669 people. Cantel Medical Corp. CEO is George L. Fotiades.
The one-year performance of Cantel Medical Corp. stock is 118.09%, while year-to-date (YTD) performance is 6.21%. CMD stock has a five-year performance of -37.61%. Its 52-week range is between 26.19 and 89.1, which gives CMD stock a 52-week price range ratio of 91.51%
Cantel Medical Corp. currently has a PE ratio of 74.60, a price-to-book (PB) ratio of 4.28, a price-to-sale (PS) ratio of 3.29, a price to cashflow ratio of 16.90, a PEG ratio of 2.32, a ROA of 2.27%, a ROC of 5.71% and a ROE of 5.92%. The company’s profit margin is 4.57%, its EBITDA margin is 17.80%, and its revenue ttm is $1.06 Billion , which makes it $25.11 revenue per share.
Of the last four earnings reports from Cantel Medical Corp., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.57 for the next earnings report. Cantel Medical Corp.’s next earnings report date is 03rd Jun 2021.
The consensus rating of Wall Street analysts for Cantel Medical Corp. is Moderate Buy (2.25), with a target price of $65.5, which is -21.80% compared to the current price. The earnings rating for Cantel Medical Corp. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cantel Medical Corp. has a dividend yield of 0.27% with a dividend per share of $0.21 and a payout ratio of 32.00%.
Cantel Medical Corp. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.16, ATR14 : 2.32, CCI20 : 0.46, Chaikin Money Flow : -0.37, MACD : -0.89, Money Flow Index : 30.10, ROC : 2.19, RSI : 50.93, STOCH (14,3) : 67.19, STOCH RSI : 1.00, UO : 44.05, Williams %R : -32.81), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cantel Medical Corp. in the last 12-months were: Ann E. Berman (Sold 5 500 shares of value $453 255 ), Brian R. Capone (Sold 300 shares of value $13 241 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.